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Clinical Context 
An 83-year-old African-American female with a history of multiple vertebral compression fractures and gastritis 
presented for the second time in two weeks with symptoms of hypercalcemia. At her first hospitalization, her 
hypercalcemia was attributed to dehydration and poor oral intake secondary to gastritis. After treatment with IV 
fluids alone, her calcium level improved from 13.0 mg/dL at admission to 11.3 mg/dL before discharge. Two weeks 
later, she was readmitted with a calcium level of 14.0 mg/dL. The patient’s daughter noted a decline in her 
mother’s cognition, and reported recent complaints of nausea, abdominal pain, and continued poor intake. The 
patient was diagnosed with hypercalcemia-induced pancreatitis and IV fluids were resumed. Endocrinology was 
consulted for management of hypercalcemia. Given a recent decline in the patient’s kidney function (creatinine 
increased to 1.74 mg/dL from 0.86 mg/dL last admission), hemoglobin of 7.9 g/dL, and the history of fractures, a 
diagnosis of multiple myeloma (MM) was highly suspected. Serum and urine protein electrophoresis were ordered. 
In the interim, serum calcium levels were not adequately controlled with IV fluids alone, and endocrinology 
recommended a single dose of IV pamidronate, the standard of care for acute hypercalcemia.1 Pharmacy declined 
to dispense pamidronate without the approval of nephrology, noting the patient’s acute kidney injury. While 
awaiting nephrology consultation, the patient’s mental status continued to decline and serum calcium levels 
spiked to 16.0 mg/dL. This case raises the question of whether bisphosphonates can be safely given for 
hypercalcemia in patients with impaired renal function. 
Clinical Question 
Can bisphosphonates be safely given to patients with hypercalcemia and renal insufficiency secondary to multiple myeloma? 
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Research Article 
Bergner R, Henrich DM, Hoffman M, et al. Renal safety and pharmacokinetics of ibandronate in multiple myeloma patients with or 
without impaired renal function. Journal of Clinical Pharmacology. 2007 Aug;47(8):942-950. doi: 10.1177/0091270007301801 
Related Literature 
The literature search began with an UpToDate search using “bisphosphonates” and “renal failure” as keywords, with review of 
current recommendations regarding their use and safety. Several articles discuss the variability of bisphosphonates with respect to 
toxicity and effectiveness for treatment of hypercalcemia of malignancy (HCM). One cited article included a randomized controlled 
trial which showed ibandronate and pamidronate to be at least equally effective in the treatment of HCM.2 Another retrospective 
study from 1999 compared renal tolerability of the various bisphosphonates, and concluded that ibandronate, pamidronate, and 
zoledronic acid were among the three least nephrotoxic bisphosphonates.3 
The search for an article to address the clinical question more directly was conducted on PubMed. Keywords used were 
“bisphosphonates”, “hypercalcemia”, and “renal failure” which yielded 153 results. Six articles were found to be highly relevant to 
the clinical question, including three review articles about the management of hypercalcemia and bisphosphonate nephrotoxicity,4-6 
and three retrospective analyses.3,7-8 Although there were numerous case reports of nephrotoxicity of these medications, only 
retrospective analyses and clinical trials were considered for appraisal. A 1996 retrospective study by Machado et al which examined 
33 patients given pamidronate for hypercalcemia of malignancy showeda transient decline in renal function which was unrelated to 
drug administration.7 Similarly, a 2006 study by Henrich et al. showed that in at least seven cases, ibandronate was well tolerated in 
patients with MM and acute renal failure.8 While both studies help support the conclusion of this clinical appraisal, their small 
sample size and retrospective nature limit their generalizability.  
The clinical trial selected for appraisal in this manuscript was found by searching PubMed with keywords “nephrotoxicity of 
bisphosphonates” while filtering for ‘clinical trials’. This search yielded eight results, only one of which was relevant to multiple 
myeloma. While the patient in question did not have a confirmed diagnosis of MM, clinical suspicion was high enough to warrant 
including this as a key parameter. The study ultimately chosen was conducted by the same authors as the Henrich, et al. case review. 
In the discussion of that article, they noted that further investigation was warranted in randomized prospective trials. This study is 
the follow-up for that statement; it is a prospective study stratifying 40 patients by their degree of renal impairment and comparing 
outcomes after treatment with ibandronate. The authors’ primary outcome of interest correlated well with this manuscript’s clinical 
question – will treatment of patients with multiple myeloma with a bisphosphonate (ibandronate) lead to nephrotoxic damage in 
patients with pre-existing renal impairment? Other articles pertaining to the usage of bisphosphonates for treatment of 
hypercalcemia of other malignancies were not chosen, as the mechanisms behind renal dysfunction in these patients are likely to be 
far too diverse compared to renal failure in MM. Additionally, the chosen article cites a similar study conducted in 1997 with 
pamidronate as the administered bisphosphonate. This article was not chosen because of the smaller sample size in study groups, 
lack of focus on MM, and lack of analysis of objective markers of renal tubular damage (i.e. β-N-acetyl-glucosaminidase (βNAG), α-
glutathione-S-transferase (αGST)).9 
Critical Appraisal 
This study is an open-label study examining the nephrotoxicity and pharmacokinetics of ibandronate in 40 patients with multiple 
myeloma. Ibandronate was chosen over other bisphosphonates as it had been shown in previous trials not to cause worsening of 
renal impairment in patients with pre-existing severe renal impairment.  The study was conducted at Medical Department A of the 
City Clinic of Ludwigshafen, Germany. The recruitment strategy for study subjects was unclear, making it difficult to rule out 
selection bias. Inclusion criteria were adults aged 18 years or older, confirmed diagnosis of MM, and an indication for 
bisphosphonate treatment (bone lesions, osteolysis, or hypercalcemia). Patients were divided into four groups based on their 
baseline creatinine clearance (CrCl) determined by the average of three accepted criteria. All four groups received ibandronate 
treatment, with the highest CrCl group serving as the primary control for comparing to patients with decreased renal function. No 
blinding or randomization was utilized because all subjects received the same treatment allocation; the outcomes of interest, kidney 
function markers, were drawn by routine laboratory protocol unlikely to be influenced by measurement bias. The primary 
MILLER MJ. Bisphosphonates can be safely given to patients with hypercalcemia and renal insufficiency 
secondary to multiple myeloma. Clin. Res. Prac. 2019 Mar 14;5(1):eP1846. doi: 
10.22237/crp/1552521660 
 
VOL 5 ISS 1 / eP1846 / MARCH 14, 2019  
doi: 10.22237/crp/1552521660 
 
 
 
ISSN: 2379-4550 
http://digitalcommons.wayne.edu/crp, © 2019 The Author(s) 
3 Licensed under Creative Commons Attribution Non-Commercial 4.0 
 
pharmacokinetic endpoints in this trial included ibandronate area under the curve (AUC), serum ibandronate t1/2, ibandronate peak 
serum level, renal clearance, total body clearance, and nonrenal clearance. Tubular damage endpoints included change in serum 
creatinine, αGST, and βNAG measured at baseline, 24, and 72 hours. All subjects completed the study, with one subject not screened 
for markers of renal toxicity due to lack of availability of urine samples.  
Despite a statistically significant increase in the ibandronate AUC over 24 hours in the lowest CrCl group relative to the highest CrCl 
group, no significant difference was found in peak serum ibandronate levels. Furthermore, there was no difference found between 
the stratified groups in markers of tubular damage at 24 and 72 hours post-infusion compared with pre-infusion. These data suggest 
that ibandronate can be used safely in MM patients across the entire range of kidney function. 
Strengths of this study include the range of subjects with respect to kidney function, and the detailed measurement protocol with 
multiple fail-safes to control for variance in individual measurements. However, there are several limitations which prevent simple 
external generalizability. These include relatively small sample size, arbitrary groupings of kidney function, and lack of racial diversity 
in the sample. With a sample of only 40 subjects, the study may lack the statistical power needed to detect small but significant 
changes in serum creatinine or tubular damage markers. Variance for these markers was high, with the reported standard error of 
the αGST and βNAG being larger in magnitude than the reported mean in all cases. Furthermore, no rationalization is provided for 
CrCl cutoffs for stages of renal insufficiency. As a result, it can be assumed that cutoffs were chosen to allow a roughly equivalent 
number of subjects in each group (~10). It is unclear if statistical significance would still be found if more recently validated CKD 
staging definitions were used (i.e. category 1 renal insufficiency being defined as CrCl >90, category 2 as CrCl 60-89, etc).10 Lastly, all 
40 study subjects were Caucasian, limiting external validity to the African-American population, which is known to have different 
kidney function parameters.11  
In addition to these study-specific limitations, it is also difficult to ensure that the lack of renal toxicity shown with ibandronate 
proxies well for other bisphosphonates shown to be less nephrotoxic. Although zoledronic acid and pamidronate were previously 
shown to be less nephrotoxic than other bisphosphonates,3 their pharmacokinetics are not perfectly analogous. For instance, the 
authors note that the AUC of pamidronate has been shown to increase 3-fold in patients with a CrCl <30 mL/min, which has an 
uncertain effect on the most severely renally impaired patients with multiple myeloma.  
Finally, this stratified controlled trial meets criteria for level 3 evidence using the SORT Criteria, due to the focus on disease-oriented 
evidence (creatinine clearance, tubular necrosis markers) as opposed to patient-oriented evidence (morbidity, mortality, symptoms, 
or quality of life).12 
Clinical Application 
When treating patients with osteolytic and hypercalcemic manifestations of multiple myeloma, renal insufficiency 
has remained an important consideration before administration of bisphosphonate therapy. In our 83-year-old 
female with mild renal insufficiency but severe altered mental status secondary to hypercalcemia, a rapid 
treatment decision was needed. Based on the results of this study, ibandronate can be safely used to treat 
hypercalcemia secondary to MM in patients with renal insufficiency. However, the application of this study to our 
patient was imperfect, as confirmed diagnosis of MM was required for study inclusion and the study did not 
include any African-American patients. Furthermore, as is commonplace, availability of specific medications in the 
hospital formulary was limited, forcing clinicians to choose between other less nephrotoxic bisphosphonates such 
as pamidronate or zoledronic acid. Ultimately, an informed discussion with the patient’s daughter was needed 
regarding proceeding with treatment. Given that the patient was too altered to communicate and the evidence for 
its safety, the daughter agreed that it was worth risking possible further nephrotoxicity from pamidronate. The 
decision was made to administer renally-dosed pamidronate, and the patient’s hypercalcemia and mental status 
rapidly improved without evidence of further kidney injury. 
Learning points: 
1. Renal insufficiency is not an absolute contraindication to bisphosphonate therapy for multiple myeloma, and 
symptomatic treatment need not be delayed on this basis. 
MILLER MJ. Bisphosphonates can be safely given to patients with hypercalcemia and renal insufficiency 
secondary to multiple myeloma. Clin. Res. Prac. 2019 Mar 14;5(1):eP1846. doi: 
10.22237/crp/1552521660 
 
VOL 5 ISS 1 / eP1846 / MARCH 14, 2019  
doi: 10.22237/crp/1552521660 
 
 
 
ISSN: 2379-4550 
http://digitalcommons.wayne.edu/crp, © 2019 The Author(s) 
4 Licensed under Creative Commons Attribution Non-Commercial 4.0 
 
2. The highest degree of evidence for renal safety exists for ibandronate, but pamidronate and zoledronic acid 
have also shown less renal toxicity than other bisphosphonates. 
3. Clinical trials may have limited external validity if the study group chosen is not particularly diverse, even 
despite adequately broad inclusion criteria. 
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